Japan database brochures

  • 109 views
Uploaded on

A propitiatory Database on Japan Pharmaceutical Industry

A propitiatory Database on Japan Pharmaceutical Industry

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
109
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. 日本の製薬企業のデータベースの紹介 MP Advisors Introduces Japan Pharma Database [MP-JPD®] To Address Unanswered FAQ About Japan Pharma Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets due to: 1. 2. 3. 4. 5. 6. Operations of various MNCs who generate significant amount of revenue but do not disclose their sales – Market Research Agencies has their limitations; no projections Disclosure of Clinical trial data – is limited/not detailed and is shared after a long gap. Lack of equivalent sites such as clinicaltrials.gov, FDA’s Orange book, etc. – company reports, various categories of CT data available at scattered sources. Mostly in Japanese. Very Difficult to get patent expiry info. from JP cos - Multiple patent extension, NO reliable Source in public domain Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas companies. Language 1000+ Products 100+ Companies 450+ Key Pipeline Candidates 1 Competitive Landscape- For Companies, Products, Pipeline Candidates & Thx Classes Landscape-
  • 2. Making Of MP-JPD® A number of reliable secondary sources scrutinized Brands/ Company/ Sales • Crecon consulting Inc. • Japan Pharmaceutical reference (JPR) • Company reports • Drugs in Japan-2011 [本医薬品集フォーラム/監修 ] Patents & R&D/Pipeline • IPDL (Industrial Property Digital Library) • Japan Pharmaceuticals Information Center (JAPIC CTI) • UMIN Clinical Trials Registry (UMIN-CTR) – in case physician belongs to university hospitals • JMA CCT – in case physician belongs to private hospitals Regulatory Related • Korosho / Kosei-roudou-sho (MHLW) • Kiko (PMDA) • Kokuho Chuoukai (NHI) • Chuikyo (Central Social Insurance Medical Council) Primary data enriched thru ~25yrs of experience base HISTORIC DATA POINTS • MP proprietary financial models (15+ companies; all majors) • In-house library of clinical data points from global companies PROJECTING FUTURE • Analyst’s projections of sales thru 2016 (~350 key products, ~60% of total market) • Analyst views on NCE/NBE pipeline (viz. based on clinical data analysis, competitive landscape) • Data acquired thru interviewing management, supply chain etc - patent expiries (~250), issues related to ongoing trails etc. • Interviews with ‘key opinion leaders’, regulators (views on price cuts, expected regulatory changes) 2
  • 3. Japan Specific Challenges ‘Japan Only’ Products ‘Japan Only’ Products Drug O riginator Lice nse e JP LaunchFY 03/10 Radicut Mitsubishi Tanabe Not licensed 2001 28.0 C oniel Kyowa Hakko Not licensed 1991 Dependence on ‘Japan Only’ Products 21.00 Gasmotin Dainippon Sumitomo Takeda Anplag 1998 20.70 Mitsubishi Tanabe Not licensed 1993 16.9 C eredist Mitsubishi Tanabe Not licensed 2000 16.3 Prorenal Ono Dainippon Su 1988 15.4 Depas Mitsubishi Tanabe Not licensed 1984 11.6 Ebastel Dainippon Sumitomo Meiji Seiku 2005 Source: MP Advisors, Company reports Company Mitsubishi Tanabe Dainippon Sumitomo Kyow a Hakko Kyorin Key products sales (¥b) products sales (sold in JP only) Weight of JP focused products (%) 201.10 190.80 106.60 83.25 91.3 72.5 22.8 45.4% 38.0% 21.4% Source: MP Advisors, Company reports 9.20 Multiple Patent Expiries Multiple Patent Extension: JP vs. US/EU Japan US EU Introducti on 1988 1984 1993 Maximum period 5 years 5 years 5 years No.of extension Multiple possible Only once Only once Multiple Only one No.of possible patent eligible for extension Source: MP Advisors, Company reports Only one • Basic patent term can be extended multiple times e.g. by adding new indications • Related patents (method of use, mfg. etc.) can also be extended multiple times • JGPMA request to JPO to Limit the extension to only one patent and only once CASE STUDY: Multiple patent extension of levofloxacin (~¥44b FY 03/10 A): Launched in Nov-93; JPO gives two entries for Cravit, showing application in 1990 (reg # 2523210) & 1993 (Reg. # 3244983 )! 1st 2nd 3rd 4th stapylococcus and other 30 bacterium June 2006 Anthrax,Pest,etc. October 2006 Typhoid Fever , Paratyphoid Fever November 2007 Legionella June 2011 Most recently Levofloxacin received mfg. approval for 500mg/100ml IV bags & 500mg/20ml injections in Oct, 2010 3
  • 4. MP-JPD® : FAQ Screenshot from MP-JPD’s Company Analysis Section ~200 products going off patent in next 4yrs (worth ~¥2tr today) will come under generic pressure & their manufacturer will look for cost optimization to remain competitive – foreign alliance for API/intermediates will be one such measure… Replace name of any product/ pipeline candidate/ thx. class/ company/ company/ time line etc. (from 1000+ products, 100+ companies & 450+ pipeline pipeline candidates) – Illustrative Examples Only • • • • • • • • • What % of sales of Toyama chemical is exposed to generics and what additional % will add-in in next 4 years? There are rumors that MSD is taking over Santen – what could be the rational and synergies between the two for products & pipeline? How many products of Abbott are actually owned by Japanese mfg. & which are these companies? Which companies lead the Chinese medicine market and how it is evolving? How the anti-diabetic market in Japan is evolving? How DPP IV & SGLT-2 inhibitors classes are shaping up & how they going to impact GLP-1 analog class? Does anti-inflammatory segment offer opportunities of API/intermediate supply? What are the opportunities for generic companies in anti-Parkinson's market? What are opportunities for the generics manufacturers in next 5 years – within this what are the opportunities for generic drugs from metabolic & cardiac thx classes? Which companies will hold their patent protected revenues in 2020? Make 1000’s of such questions and MP-JPD® will answer them! 1000’ MP- JPD® For Queries & Subscription, Contact: Vrunda Shah | vrunda@mpadvisor.com |+91.265.232.0059 | www.mpadvisor.com MP Advisors, B2-3, Alkapuri Arcade, R C Dutt Road, Vadodara-390007 INDIA B2Vadodara- 4